GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: November 6, 2004, 19:23:00 ; Search time 62.6562 Seconds
(without alignments)
28.627 Million cell updates/sec

Title: US-10-618-644-5
Perfect score: 27
Sequence: 1 TPRVF 5

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 358729299 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_23Sep04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	27	100.0	5	5	ABB81807	Abb81807 Soybean a
2	27	100.0	7	2	AAR13594	Aar13594 Angiotens
3	27	100.0	14	4	AAB64509	Aab64509 Gene 25 h
4	27	100.0	49	4	AAM17754	Aam17754 Peptide #
5	27	100.0	49	4	ABB36778	Abb36778 Peptide #
6	27	100.0	49	4	AAM30265	Aam30265 Peptide #
7	27	100.0	49	4	ABB31563	Abb31563 Peptide #
8	27	100.0	49	4	ABB22104	Abb22104 Protein #
9	27	100.0	49	4	AAM69928	Aam69928 Human bon
10	27	100.0	49	4	AAM57526	Aam57526 Human bra
11	27	100.0	49	4	ABG51626	Abg51626 Human liv
12	27	100.0	49	4	AAM05410	Aam05410 Peptide #
13	27	100.0	49	5	ABG39558	Abg39558 Human pep
14	27	100.0	65	3	AAG22500	Aag22500 Arabidops
15	27	100.0	70	4	AAM81712	Aam81712 Human hae
16	27	100.0	70	4	AAM81457	Aam81457 Human hae
17	27	100.0	105	4	AAU58073	Aau58073 Propionib
18	27	100.0	105	6	ABM54592	Abm54592 Propionib
19	27	100.0	106	3	AAG22499	Aag22499 Arabidops
20	27	100.0	112	4	AAO03893	Aao03893 Human pol
21	27	100.0	113	3	AAG22498	Aag22498 Arabidops
22	27	100.0	115	4	AAM81529	Aam81529 Human hae
23	27	100.0	115	4	AAM81079	Aam81079 Human hae
24	27	100.0	115	4	AAM81657	Aam81657 Human hae
25	27	100.0	115	4	AAM81175	Aam81175 Human hae
26	27	100.0	143	4	AAO00557	Aao00557 Human pol
27	27	100.0	167	5	ADK34674	Adk34674 Novel hum
28	27	100.0	186	7	ADC32883	Adc32883 Human nov
29	27	100.0	206	2	AAW17978	Aaw17978 dTDP-4-ke
30	27	100.0	207	4	ABB06925	Abb06925 Micromono
31	27	100.0	207	6	ABP99315	Abp99315 Orthosomy
32	27	100.0	214	6	ABR01485	Abr01485 Human ant
33	27	100.0	237	4	AAG93005	Aag93005 C glutami
34	27	100.0	257	7	ADD13575	Add13575 C. glutam
35	27	100.0	275	3	AAG51538	Aag51538 Arabidops
36	27	100.0	275	3	AAG04522	Aag04522 Arabidops
37	27	100.0	275	5	ABB92466	Abb92466 Herbicida
38	27	100.0	316	3	AAG04521	Aag04521 Arabidops
39	27	100.0	316	3	AAG51537	Aag51537 Arabidops
40	27	100.0	324	3	AAG04520	Aag04520 Arabidops
41	27	100.0	332	5	ABG96259	Abg96259 Maize per
42	27	100.0	347	5	ABG96251	Abg96251 Maize per
43	27	100.0	362	7	ABO68987	Abo68987 Pseudomon
44	27	100.0	376	7	ADC31181	Adc31181 Human nov
45	27	100.0	376	7	ADM04333	Adm04333 Human pro

ALIGNMENTS

RESULT 1
ABB81807
ID ABB81807 standard; peptide; 5 AA.
XX
AC ABB81807;
XX
DT 23-SEP-2002 (first entry)
XX
DE Soybean angiotensin converting enzyme inhibitory peptide #5.
XX
KW Soybean; angiotensin converting enzyme inhibitor; hypertension;
KW hypotensive; taste.
XX
OS Glycine max.
XX
PN WO200255546-A1.
XX
PD 18-JUL-2002.
XX
PF 15-JAN-2002; 2002WO-JP000194.
XX
PR 16-JAN-2001; 2001JP-00007400.
PR 04-OCT-2001; 2001JP-00308974.
XX
PA (AJIN) AJINOMOTO CO INC.
XX
PI Kodera T, Nio N;
XX
DR WPI; 2002-520117/55.
XX
PT Peptides, useful as hypotensive agents or in health foods.
XX
PS Claim 1; Page 19; 43pp; Japanese.
XX
CC The invention relates to a novel set of peptides and their salts. The
CC peptides of the invention have hypotensive activity. The peptides are
CC used as hypotensive agents or in health foods, and have favourable taste.
CC The present sequence represents a peptide of the invention, having
CC angiotensin converting enzyme inhibitory activity
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 27; DB 5; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPRVF 5
|||||

```
Db          1 TPRVF 5


RESULT 2
AAR13594
ID   AAR13594 standard; peptide; 7 AA.
XX
AC   AAR13594;
XX
DT   25-MAR-2003  (revised)
DT   01-NOV-1991  (first entry)
XX
DE   Angiotensin converting enzyme inhibitory heptapeptide.
XX
KW   Hypertension; soy bean.
XX
OS   Glycine max.
XX
PN   JP03167198-A.
XX
PD   19-JUL-1991.
XX
PF   24-NOV-1989;   89JP-00303294.
XX
PR   24-NOV-1989;   89JP-00303294.
XX
PA   (NORQ ) NORINSHO KK.
XX
DR   WPI; 1991-256668/35.
XX
PT   Angiotensin converting enzyme inhibitory substance - comprises hexa and
PT   hepta:peptide(s) isolated from soy bean protein, used for treating
PT   hypertension as food prod.
XX
PS   Claim 1; Page 1; 9pp; Japanese.
XX
CC   The peptide and its salts can be used to effectively inhibit the activity
CC   of angiotensin converting enzyme. It can be administered as food, since
CC   it is safe and free from side effects, being isolated from soy bean
CC   protein. It has a mild decreasing effect on blood pressure and may also
CC   be used to prevent hypertension. See also AAR13595. (Updated on 25-MAR-
CC   2003 to correct PA field.)
XX
SQ   Sequence 7 AA;

  Query Match             100.0%;  Score 27;  DB 2;  Length 7;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TPRVF 5
              |||||
Db          3 TPRVF 7


RESULT 3
AAB64509
ID   AAB64509 standard; protein; 14 AA.
XX
AC   AAB64509;
XX
DT   23-MAR-2001  (first entry)
XX
DE   Gene 25 human secreted protein homologous amino acid sequence #147.
XX
KW   Human; secreted protein; diagnosis; immunosuppressive; antiarthritic;
KW   antirheumatic; antiproliferative; cytostatic; cardiant; vasotropic;
KW   cerebroprotective; nootropic; neuroprotective; antibacterial; virucide;
KW   fungicide; ophthalmological; autoimmune disease; rheumatoid arthritis;
KW   hyperproliferative disorder; neoplasm; cardiovascular disorder;
KW   cardiac arrest; cerebrovascular disorder; cerebral ischaemia; infection;
KW   angiogenesis; nervous system disorder; Alzheimer's disease; skin aging;
KW   ocular disorder; corneal infection; wound healing; food additive;
KW   preservative.
XX
OS   Homo sapiens.
XX
PN   WO200077255-A1.
XX
PD   21-DEC-2000.
XX
PF   01-JUN-2000; 2000WO-US014926.
XX
PR   11-JUN-1999;   99US-0138628P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ruben SM,  Komatsoulis GA;
XX
DR   WPI; 2001-025337/03.
XX
PT   Isolated nucleic acid molecule encoding a human secreted protein is used
PT   in preventing, treating or ameliorating a medical condition.
XX
PS   Disclosure; Page 564; 593pp; English.
XX
CC   The polynucleotide sequences given in AAF32699 to AAF32747 encode the
CC   human secreted proteins given in AAB64422 to AAB64470. AAB64471 to
CC   AAB64548 represent human secreted polypeptide sequences and proteins
CC   homologous to them, which are given in the exemplification of the present
CC   invention. Human secreted proteins have activities based on the tissues
CC   and cells the genes are expressed in. Examples of activities include:
CC   antiarthritic; immunosuppressive; antirheumatic; antiproliferative;
CC   cytostatic; cardiant; vasotropic; cerebroprotective; nootropic;
CC   neuroprotective; antibacterial; virucide; fungicide; and
CC   ophthalmological. The polynucleotides and polypeptides can be used to
CC   prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC   rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
CC   in diagnosing a pathological condition or susceptibility to a
CC   pathological condition. Disorders which are diagnosed or treated include
CC   autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
CC   disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
CC   e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC   angiogenesis, nervous system disorders e.g. Alzheimer's disease,
CC   infections caused by bacteria, viruses and fungi and ocular disorders
CC   e.g. corneal infection. The polypeptides can also be used to aid wound
CC   healing and epithelial cell proliferation, to prevent skin aging due to
CC   sunburn, to maintain organs before transplantation, for supporting cell
CC   culture of primary tissues, to regenerate tissues and in chemotaxis. The
CC   polypeptides can also be used as a food additive or preservative to
CC   increase or decrease storage capabilities. AAF32690 to AAF32698 and
CC   AAB64421 represent sequences used in the exemplification of the present
CC   invention
XX
SQ   Sequence 14 AA;

  Query Match             100.0%;  Score 27;  DB 4;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 18;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TPRVF 5
              |||||
Db          4 TPRVF 8


RESULT 4
AAM17754
ID   AAM17754 standard; protein; 49 AA.
XX
AC   AAM17754;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Peptide #4188 encoded by probe for measuring cervical gene expression.
XX
KW   Probe; human; microarray; gene expression; cervical epithelial cell;
KW   cervical cancer.
```

XX
OS Homo sapiens.
XX
PN WO200157278-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000670.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488901/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human cervical epithelial cells.
XX
PS Claim 27; SEQ ID NO 22580; 487pp; English.
XX
CC The present invention relates to human single exon nucleic acid probes
CC (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC can be used to produce a single exon microarray, which can be used for
CC measuring human gene expression in a sample derived from human cervical
CC epithelial cells. By measuring gene expression, the probes are therefore
CC useful in grading and/or staging of diseases of the cervix, notably
CC cervical cancer. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 49 AA;

```
  Query Match             100.0%;  Score 27;  DB 4;  Length 49;
  Best Local Similarity   100.0%;  Pred. No. 66;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TPRVF 5
              |||||
Db         19 TPRVF 23
```

RESULT 5
ABB36778
ID ABB36778 standard; peptide; 49 AA.
XX
AC ABB36778;
XX
DT 04-FEB-2002 (first entry)
XX
DE Peptide #4284 encoded by human foetal liver single exon probe.
XX
KW Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS Homo sapiens.
XX
PN WO200157277-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000669.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483447/52.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human fetal liver.
XX
PS Claim 27; SEQ ID NO 29413; 639pp + Sequence Listing; English.
XX
CC The invention relates to a single exon nucleic acid probe for measuring
CC human gene expression in a sample derived from human foetal liver. The
CC single exon nucleic acid probes may be used for predicting, measuring and
CC displaying gene expression in samples derived from human fetal liver. The
CC present sequence is a peptide encoded by a single exon nucleic acid probe
CC of the invention. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 49 AA;

```
  Query Match             100.0%;  Score 27;  DB 4;  Length 49;
  Best Local Similarity   100.0%;  Pred. No. 66;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TPRVF 5
              |||||
Db         19 TPRVF 23
```

RESULT 6
AAM30265
ID AAM30265 standard; protein; 49 AA.
XX
AC AAM30265;
XX
DT 17-OCT-2001 (first entry)
XX
DE Peptide #4302 encoded by probe for measuring placental gene expression.
XX
KW Probe; microarray; human; placenta; antenatal diagnosis;
KW genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000663.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488897/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human placenta.

```
XX
PS   Claim 27; SEQ ID NO 30534; 654pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes (SENP:
CC   see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for producing a microarray for
CC   predicting, measuring and displaying gene expression in samples derived
CC   from human placenta. The probes are useful for antenatal diagnosis of
CC   human genetic disorders
XX
SQ   Sequence 49 AA;

  Query Match             100.0%;  Score 27;  DB 4;  Length 49;
  Best Local Similarity   100.0%;  Pred. No. 66;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TPRVF 5
              |||||
Db         19 TPRVF 23


RESULT 7
ABB31563
ID   ABB31563 standard; peptide; 49 AA.
XX
AC   ABB31563;
XX
DT   01-FEB-2002  (first entry)
XX
DE   Peptide #4214 encoded by breast cell single exon nucleic acid probe.
XX
KW   Human; microarray; single exon probe; gene expression; breast; disease;
KW   cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157271-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000662.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-496933/54.
XX
PT   New spatially-addressable set of single exon nucleic acid probes, useful
PT   for measuring gene expression in sample derived from human breast,
PT   comprises number of single exon nucleic acid probes.
XX
PS   Claim 27; SEQ ID NO 14531; 327pp + Sequence Listing; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human breast and BT 474 cells. The method involves contacting the
CC   probes with a collection of detectably labelled nucleic acids derived
CC   from mRNA of human breast, and then measuring the label bound to each
CC   probe of the microarray. The probes are useful for verifying the
CC   expression of regions of genomic DNA predicted to encode proteins. They
CC   are useful for gene discovery, and for determining predisposition and/or
CC   prognosing breast disease. Gene expression analysis is useful for
CC   assessing the toxicity of chemical agents on cells. The microarray of
CC   this invention presents a far greater diversity of probes for measuring
CC   gene expression, with far less bias than expressed sequence tag
CC   microarrays. The method is suitable for rapid production of functional
CC   information from genomic sequence. The present sequence is a peptide
CC   encoded by a single exon nucleic acid probe of the invention. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 49 AA;

  Query Match             100.0%;  Score 27;  DB 4;  Length 49;
  Best Local Similarity   100.0%;  Pred. No. 66;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TPRVF 5
              |||||
Db         19 TPRVF 23


RESULT 8
ABB22104
ID   ABB22104 standard; protein; 49 AA.
XX
AC   ABB22104;
XX
DT   23-JAN-2002  (first entry)
XX
DE   Protein #4103 encoded by probe for measuring heart cell gene expression.
XX
KW   Human; gene expression; heart; microarray; vascular system;
KW   cardiovascular disease; hypertension; cardiac arrhythmia;
KW   congenital heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157274-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000666.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488899/53.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   hearts.
XX
PS   Claim 15; SEQ ID NO 23874; 530pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes for
CC   measuring human gene expression in a sample derived from human heart (see
CC   ABA21535-ABA41305). The present sequence is a protein encoded by one such
CC   probe. The probes may be used for predicting, measuring and displaying
CC   gene expression in samples derived from the human heart via microarrays.
CC   By measuring gene expression, the probes are useful for predicting,
CC   diagnosing, grading, staging, monitoring and prognosing diseases of the
CC   human heart and vascular system e.g. cardiovascular disease,
CC   hypertension, cardiac arrhythmias and congenital heart disease. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
```

```
SQ   Sequence 49 AA;

  Query Match             100.0%;  Score 27;  DB 4;  Length 49;
  Best Local Similarity   100.0%;  Pred. No. 66;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TPRVF 5
              |||||
Db         19 TPRVF 23


RESULT 9
AAM69928
ID   AAM69928 standard; protein; 49 AA.
XX
AC   AAM69928;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human bone marrow expressed probe encoded protein SEQ ID NO: 30234.
XX
KW   Human; bone marrow expressed exon; gene expression analysis; probe;
KW   microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS   Homo sapiens.
XX
PN   WO200157276-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000668.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488900/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human bone marrow.
XX
PS   Example 4; SEQ ID NO 30234; 658pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   bone marrow. They can be used to measure gene expression in bone marrow
CC   samples, which may enable the improved diagnosis and treatment of cancers
CC   such as lymphoma, leukaemia and myeloma. The present sequence is a
CC   protein encoded by one of the probes of the invention
XX
SQ   Sequence 49 AA;

  Query Match             100.0%;  Score 27;  DB 4;  Length 49;
  Best Local Similarity   100.0%;  Pred. No. 66;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TPRVF 5
              |||||
Db         19 TPRVF 23


RESULT 10
AAM57526
ID   AAM57526 standard; protein; 49 AA.
XX
AC   AAM57526;
XX
DT   05-NOV-2001  (first entry)
XX
DE   Human brain expressed single exon probe encoded protein SEQ ID NO: 29631.
XX
KW   Human; brain expressed exon; gene expression analysis; probe; microarray;
KW   Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157275-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000667.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483446/52.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   brains.
XX
PS   Example 4; SEQ ID NO 29631; 650pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   brain. They can be used to measure gene expression in brain cell samples,
CC   which may enable the diagnosis and improved treatment of nervous system
CC   diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC   epilepsy and cancers. The present sequence is a protein encoded by one of
CC   the probes of the invention
XX
SQ   Sequence 49 AA;

  Query Match             100.0%;  Score 27;  DB 4;  Length 49;
  Best Local Similarity   100.0%;  Pred. No. 66;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TPRVF 5
              |||||
Db         19 TPRVF 23


RESULT 11
ABG51626
ID   ABG51626 standard; peptide; 49 AA.
XX
AC   ABG51626;
XX
DT   25-FEB-2003  (first entry)
XX
DE   Human liver peptide, SEQ ID No 30274.
XX
KW   Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW   hypercholesterolaemia; coronary heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157273-A2.
XX
PD   09-AUG-2001.
```

XX
PF 30-JAN-2001; 2001WO-US000664.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488898/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human adult liver.
XX
PS Claim 27; SEQ ID NO 30274; 658pp; English.
XX
CC The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC measuring human gene expression in a sample derived from human adult
CC liver, comprising one of 13109 defined nucleotide sequences given in the
CC specification (or complements/ fragments). The probe hybridises at high
CC stringency to a nucleic acid molecule expressed in the human adult liver.
CC (I) may be used for predicting, measuring and displaying gene expression
CC in samples derived from human adult liver. The genes identified may be
CC involved in genetic liver diseases such as cirrhosis,
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC associated with coronary heart disease. ABG47348-ABG59930 represent human
CC liver single exon encoded peptides of the invention. Note: The sequence
CC information for this patent does not appear in the printed specification
CC but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 49 AA;

Query Match 100.0%; Score 27; DB 4; Length 49;
Best Local Similarity 100.0%; Pred. No. 66;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPRVF 5
|||||
Db 19 TPRVF 23

RESULT 12
AAM05410
ID AAM05410 standard; protein; 49 AA.
XX
AC AAM05410;
XX
DT 09-OCT-2001 (first entry)
XX
DE Peptide #4092 encoded by probe for measuring breast gene expression.
XX
KW Probe; human; breast disease; breast cancer; development disorder;
KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS Homo sapiens.
XX
PN WO200157270-A2.
XX
PD 09-AUG-2001.
XX
PF 29-JAN-2001; 2001WO-US000661.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-476286/51.
XX
PT Novel single exon nucleic acid probe used to measuring gene expression in
PT a human breast.
XX
PS Claim 27; SEQ ID NO 14150; 322pp; English.
XX
CC The present invention relates to novel single exon nucleic acid probes
CC (see AAI00010-AAI10067). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for measuring human gene expression in
CC a human breast sample, where the probe hybridises at high stringency to a
CC nucleic acid expressed in the human breast. The probes are useful for
CC predicting, diagnosing, grading, staging, monitoring and prognosing
CC diseases of the human breast, particularly those diseases with polygenic
CC aetiology. The diseases include: breast cancer, disorders of development,
CC inflammatory diseases of the breast, fibrocystic changes, proliferative
CC breast disease and non-carcinoma tumours. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 49 AA;

Query Match 100.0%; Score 27; DB 4; Length 49;
Best Local Similarity 100.0%; Pred. No. 66;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPRVF 5
|||||
Db 19 TPRVF 23

RESULT 13
ABG39558
ID ABG39558 standard; peptide; 49 AA.
XX
AC ABG39558;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human peptide encoded by genome-derived single exon probe SEQ ID 29223.
XX
KW Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW chronic obstructive pulmonary disease; interstitial lung disease;
KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW primary ciliary dyskinesis; pulmonary hypertension;
KW hyaline membrane disease.
XX
OS Homo sapiens.
XX
PN WO200186003-A2.
XX
PD 15-NOV-2001.
XX
PF 30-JAN-2001; 2001WO-US000665.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2002-114183/15.
XX
PT Spatially-addressable set of single exon nucleic acid probes, used to
PT measure gene expression in human lung samples.
XX
PS Claim 27; SEQ ID NO 29223; 634pp; English.
XX
CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human lung comprising single exon nucleic acid probes having one of
CC 12614 nucleic acid sequences mentioned in the specification, or their
CC complements or the 12387 open reading frames derived from the 12614
CC probes. Also included are a microarray comprising the novel set of probes
CC ; the novel set of probes which hybridise at high stringency to a nucleic
CC acid expressed in the human lung; measuring gene expression in a sample
CC derived from human lung, comprising (a) contacting the array with a
CC collection of detectably labeled nucleic acids derived from human lung
CC mRNA, and (b) measuring the label detectably bound to each probe of the
CC array; identifying exons in a eukaryotic genome, comprising (a)
CC algorithmically predicting at least one exon from genomic sequences of
CC the eukaryote; and (b) detecting specific hybridisation of detectably
CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC having a fragment identical to the predicted exon, the probe is included
CC in the above mentioned microarray; assigning exons to a single gene,
CC comprising (a) identifying exons from genomic sequence by the method
CC above and (b) measuring the expression of each of the exons in several
CC tissues and/or cell types using hybridisation to a single exon
CC microarrays having a probe with the exon, where a common pattern of
CC expression of the exons in the tissues and/or cell types indicates that
CC the exons should be assigned to a single gene; a peptide comprising one
CC of 12011 sequences, mentioned in the specification, or encoded by the
CC probes/open reading frames (ORF). The probes are used for gene expression
CC analysis, and for identifying exons in a gene, particularly using human
CC lung derived mRNA and for the study of lung diseases such as asthma, lung
CC cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC histiocytosis, lymphangioleiomyomtosis, pulmonary alveolar proteinosis,
CC Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC dyskinesis, pulmonary hypertension and hyaline membrane disease. The
CC present sequence is a peptide/protein encoded by a single exon probe of
CC the invention. Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 49 AA;

Query Match 100.0%; Score 27; DB 5; Length 49;
Best Local Similarity 100.0%; Pred. No. 66;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPRVF 5
|||||
Db 19 TPRVF 23

RESULT 14
AAG22500
ID AAG22500 standard; protein; 65 AA.
XX
AC AAG22500;
XX
DT 17-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 25452.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.

PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 27; DB 3; Length 65;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 TPRVF 5
              |||||
Db         21 TPRVF 25
```

RESULT 15
AAM81712
ID AAM81712 standard; protein; 70 AA.
XX
AC AAM81712;
XX
DT 13-NOV-2001 (first entry)
XX
DE Human haematological malignancy-related antigen #1410.
XX
KW Human; cytostatic; vascular; gene therapy; vaccine; lymphoma;
KW haematological malignancy; antigen; chronic lymphocytic leukaemia;
KW follicular lymphoma; Hodgkin's lymphoma; non-Hodgkin's lymphoma.
XX
OS Homo sapiens.
XX

PN WO200164886-A2.
XX
PD 07-SEP-2001.
XX
PF 01-MAR-2001; 2001WO-US007272.
XX
PR 01-MAR-2000; 2000US-0186126P.
PR 17-MAR-2000; 2000US-0190479P.
PR 27-APR-2000; 2000US-0200545P.
PR 28-APR-2000; 2000US-0200303P.
PR 28-APR-2000; 2000US-0200779P.
PR 01-MAY-2000; 2000US-0200999P.
PR 04-MAY-2000; 2000US-0202084P.
PR 22-MAY-2000; 2000US-0206201P.
PR 14-JUL-2000; 2000US-0218950P.
PR 03-AUG-2000; 2000US-0222903P.
PR 04-AUG-2000; 2000US-0223416P.
PR 07-AUG-2000; 2000US-0223378P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Gaiger A, Algate PA, Mannion J;
XX
DR WPI; 2001-514842/56.
XX
PT Compositions and methods for the detection of hematological malignancies,
PT e.g. chronic lymphocytic leukemia, lymphoma, follicular lymphoma and
PT Hodgkin's and T/B cell non-Hodgkin's lymphoma.
XX
PS Claim 1; Page 1072-1073; 1252pp; English.
XX
CC The present invention relates to compositions and methods for the
CC detection, diagnosis and therapy of haematological malignancies. The
CC present sequence is the protein sequence of a human haematological
CC malignancy related antigen. The methods of the present invention comprise
CC detecting the presence of haematological malignancy related antigen(s) in
CC a sample obtained from the patient (an increased level of the
CC polypeptide, compared to an unaffected individual, is indicative of an
CC increased risk). Haematological malignancies which can be treated using
CC the present invention are chronic lymphocytic leukaemia, lymphoma,
CC follicular lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma and T/B
CC cell non-Hodgkin's lymphoma
XX
SQ Sequence 70 AA;

Query Match 100.0%; Score 27; DB 4; Length 70;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TPRVF 5
|||||
Db 54 TPRVF 58

Search completed: November 6, 2004, 19:45:51
Job time : 65.6562 secs